McCulloch Kevin sold $120K of XERS
McCulloch Kevin (See Remarks) sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.02 ($0.12M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the 10b5-1 structure typically limits interpretability as a negative fundamental signal.
What to watch
The filing does not indicate whether the insider’s remaining holdings are large relative to typical patterns, nor does it provide any company-specific operational update.
Background
The article is an SEC Form 4 insider transaction disclosure for Xeris Biopharma Holdings, Inc.
Ticker impact
Xeris Biopharma Holdings disclosed an officer open-market sale of 15,000 shares at $8.0160 on a pre-arranged 10b5-1 plan.
Likely minimal, with any impact confined to short-term sentiment rather than a fundamental repricing.
Form 4 insider sales are common and the filing specifies a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive information.
Market effects
No clear sector read-through from a single routine 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still reflect internal risk management or liquidity needs, which some traders may interpret as caution.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderMcCulloch Kevin
Officer who sold 15,000 shares in an open-market transaction under a 10b5-1 plan.
